Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to investigate the safety and efficacy of alitretinoin in chronic hand eczema that is refractory to topical corticosteroids.


Clinical Trial Description

Chronic hand eczema is a frequent and distressing disease. The course of the disease is of chronic-relapsing nature. In a phase III study alitretinoin was clinically effective for patients with severe chronic hand eczema refractory to topical treatment. This study investigates the safety and efficacy of alitretinoin who previously have participated in a clinical trial involving alitretinoin. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00519675
Study type Interventional
Source Basilea Pharmaceutica
Contact
Status Completed
Phase Phase 3
Start date May 2007

See also
  Status Clinical Trial Phase
Completed NCT01257061 - Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment Phase 3
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Recruiting NCT05439577 - A Multicentre Study to Explore the Efficacy and Safety of Mucopolysaccharide Polysulfate Cream in Patients With Eczema
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT02075632 - Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream Phase 2
Completed NCT00143819 - Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis Phase 2
Recruiting NCT01631617 - Effects of Treatments on Atopic Dermatitis Phase 2
Not yet recruiting NCT04520308 - An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis Phase 4
Completed NCT04358224 - The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment Phase 4
Not yet recruiting NCT05990725 - Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis Phase 3
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Completed NCT04023084 - Response of Children With Atopic Dermatitis (Eczema) to Eucrisa Phase 4
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Completed NCT05583019 - Atopic Dermatitis With Accelerometry and Polysomnography (ADAP)
Recruiting NCT03293030 - Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis Phase 4
Completed NCT02002871 - Blue Light for Treating Eczema N/A
Completed NCT01420705 - Bacille Calmette-Guérin (BCG) Vaccine and Atopy N/A
Recruiting NCT01012453 - A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema N/A